RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
GW Pharmaceuticals Stock

GW Pharmaceuticals Stocks 2025

GW Pharmaceuticals Stocks

375.59 M

Ticker

GWPH

ISIN

US36197T1034

WKN

A1T980

In 2025, GW Pharmaceuticals had 375.59 M outstanding stocks, a 0% change from the 375.59 M stocks in the previous year.

The GW Pharmaceuticals Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2025e375.59
2024e375.59
2023e375.59
2022e375.59
2021e375.59
2020375.59
2019371.58
2018340.4
2017303.6
2016270.4
2015246.4
2014210.4

GW Pharmaceuticals shares outstanding

The number of shares was GW Pharmaceuticals in 2024 — This indicates how many shares 375.586 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue GW Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates GW Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of GW Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating GW Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

GW Pharmaceuticals Aktienanalyse

What does GW Pharmaceuticals do?

GW Pharmaceuticals PLC is a British company that has been involved in the development and manufacturing of prescription medications based on cannabis since 1998. The company is a global leader in the research of medical cannabis and is headquartered in Cambridge. The history of GW Pharmaceuticals traces back to the founding of the company by Dr. Geoffrey Guy, who focused on the medical use of cannabis. In its early years, the company focused on developing medicinal cannabis strains with high levels of cannabinoids, such as THC or CBD. A pivotal moment for the company was the approval of Sativex in 2010, a medication for the treatment of spastic symptoms in multiple sclerosis. This was the first cannabis-based medication to be approved by a regulatory authority. Since then, GW Pharmaceuticals has expanded its portfolio of products and is involved in various areas, including the treatment of epilepsy, autism, pain, insomnia, and cancer. The company has several medications in late-stage clinical development and plans to bring more medications to the market. GW Pharmaceuticals' business model is based on researching, manufacturing, and selling medical cannabis. The company is an innovative pioneer in this field and works closely with health authorities and medical professionals to ensure the safety and efficacy of its products. GW Pharmaceuticals operates in several sectors, including the development of medical cannabis, the manufacturing of medications, and collaboration with health authorities and medical professionals. The company strives to develop high-quality and safe products that improve patients' quality of life. One of GW Pharmaceuticals' key products is Epidiolex, a medication for the treatment of severe forms of epilepsy in children. The medication contains CBD, one of the compounds found in medical cannabis, and has been approved by the U.S. Food and Drug Administration (FDA). Another important product of GW Pharmaceuticals is Sativex, a spray for the treatment of spastic symptoms in multiple sclerosis. The medication contains a combination of THC and CBD and is approved in several countries. GW Pharmaceuticals also has products in the pipeline targeting the treatment of autism, pain, insomnia, and cancer. The company is committed to advancing the use of medical cannabis and its compounds in medical practice and contributing to the improvement of health. Overall, GW Pharmaceuticals has made a significant contribution to the research and development of medical cannabis and has established itself as a leader in this field. The company is dedicated to developing high-quality medications that improve patients' lives and contribute to improving health. GW Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating GW Pharmaceuticals's Shares Outstanding

GW Pharmaceuticals's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in GW Pharmaceuticals’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding GW Pharmaceuticals’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in GW Pharmaceuticals’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about GW Pharmaceuticals stock

How many stocks are there of GW Pharmaceuticals?

The current number of stocks of GW Pharmaceuticals is 375.59 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of GW Pharmaceuticals are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of GW Pharmaceuticals evolved in recent years?

The number of shares of GW Pharmaceuticals has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. GW Pharmaceuticals as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of GW Pharmaceuticals?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does GW Pharmaceuticals pay?

Over the past 12 months, GW Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, GW Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of GW Pharmaceuticals?

The current dividend yield of GW Pharmaceuticals is .

When does GW Pharmaceuticals pay dividends?

GW Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of GW Pharmaceuticals?

GW Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of GW Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is GW Pharmaceuticals located?

GW Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von GW Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of GW Pharmaceuticals from 1/22/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/22/2025.

When did GW Pharmaceuticals pay the last dividend?

The last dividend was paid out on 1/22/2025.

What was the dividend of GW Pharmaceuticals in the year 2024?

In the year 2024, GW Pharmaceuticals distributed 0 USD as dividends.

In which currency does GW Pharmaceuticals pay out the dividend?

The dividends of GW Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The GW Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von GW Pharmaceuticals

Our stock analysis for GW Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of GW Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.